Navigation Links
Ranbaxy Launches Omeprazole 40 mg Capsules
Date:7/28/2008

GURGAON, India and PRINCETON, N.J., July 28 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India announced today that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40 mg Capsules in the U.S. healthcare system. Omeprazole 40 mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. The most common side effects of Prilosec(R) are headache, diarrhea and abdominal pain. Prilosec(R) 40 mg had sales in the U.S. market of $204.2 million (IMS: March 2008 MAT).

"We welcome the opportunity to market an authorized generic of Omeprazole 40 mg capsules that will be commercialized immediately to all classes of trade in the U.S. healthcare system under the Ranbaxy label," said Jim Meehan, Vice President of Sales and Distribution for RPI. "We will offer this product as an affordable and accessible generic formulation to patients requiring this medication."

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an ex
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
2. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
3. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
5. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
6. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
7. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
8. GeneNews launches worlds first blood test for colorectal cancer screening
9. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
10. Health Market Science Launches Clinical Investigators(TM)
11. SAFC Supply Solutions Launches REACH-Compliant Products and Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
(Date:7/24/2014)... , July 24, 2014   Cypher ... today the appointment of Adam Simpson ... Genomics provides rapid and comprehensive annotation and interpretation ... clinical reporting. "Cypher,s technology has the ... healthcare by enhancing diagnostic accuracy, optimizing therapeutic approaches ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... MADISON First, a full disclosure: Ive been hawking the concept ... a couple of years, so its no surprise I would think ... finding common ground. , ,Then again, its still something of ... dont have to be a student of Wisconsin history to know ...
... - There is both a new World Wide Web ... branding/marketing professionals would be wise to adapt to, according to ... conference, which is being held at Monona Terrace , ... era where technology has helped put the consumer in charge. ...
... When there was a monopoly phone service prior to the ... "give exclusivity in the territory and we will provide universal ... to a geographic subscriber base, the traditional phone companies ensured ... a fair price. There was one price across the board. ...
Cached Biology Technology:A (modern) Tale of Two Cities: Milwaukee and Madison inch together 2A (modern) Tale of Two Cities: Milwaukee and Madison inch together 3Marketers advised to engage "search economy" 2Marketers advised to engage "search economy" 3Does redefining universal service help bridge the digital divide? 2Does redefining universal service help bridge the digital divide? 3Does redefining universal service help bridge the digital divide? 4Does redefining universal service help bridge the digital divide? 5
(Date:7/25/2014)... SPRINGS, Florida , July 25, 2014 ... as more consumers are turning to digital technology for ... Inc. (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ... Inc. (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... different effects on different species of fish, according ... Bristol and Exeter which tested fish anti-predator behaviour. ... flying seagull predator model when exposed to additional ... minnows. , Lead author Dr Irene Voellmy ... levels in many aquatic environments have increased substantially ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... America is pleased to announce that nine students, research ... Annual Drosophila Research Conference in Washington, D.C., April 7-11, ... place awards for each of three academic levels: postdoctoral, ... undergraduate student research was included for review to receive ...
... Disadvantaged urban preschoolers aren,t only at risk for failure in ... and athletic fields as well, research suggests. A new ... disadvantaged preschoolers from two urban areas showed significant developmental delays ... catching. That means that they are at risk of ...
... capturing the sun,s rays through solar panels on their roofs used ... in order to help save the planet. But now there is ... eyesore, says a Spanish-German partnership, which has developed a virtually invisible ... "You don,t see the film at all it,s marvellous," says ...
Cached Biology News:Genetics Society of America announces award recipients at 51st Annual Drosophila Conference 286 percent of disadvantaged preschoolers lack basic motor skills 286 percent of disadvantaged preschoolers lack basic motor skills 3Roof integrated solar energy 2Roof integrated solar energy 3
... Chromogen system consists of [5-Bromo-4-Chloro-3-,Indolyl ... a single component,solution. The ready-to-use ... presence of alkaline phosphatase to ... minimal background noise. ,The System ...
... Corning CellBIND surface is produced by a ... hydrophilic surface giving more consistent, even cell ... enhances cell attachment and growth uunder difficult ... • CellBIND may provide a more ecominic ...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Biology Products: